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ABSTRACT – We evaluated the efﬁcacy and tolerability of ruﬁnamide
adjunctive therapy in children with refractory generalised epilepsy. The
study cohort consisted of 20 patientswith Lennox-Gastaut syndrome, 5with
Dravet syndrome, and 28 with unclassiﬁed refractory generalised epilepsy.
Patients with more than 50% seizure reduction at three and six months
were deﬁned as responders. The overall response rate was 37.7% at three
months and 34.0% at six months. At three months, patients with Lennox-
Gastaut syndrome (40.0%) and epilepsy with spasms/tonic seizures (38.5%)
showedhigher response rates than thosewithDravet syndrome (20.0%) and
epilepsy with myoclonic seizures (20.0%). High response rates in patients
with Lennox-Gastaut syndrome (30.0%) and epilepsy with spasms/tonic
seizures (38.5%) were sustained throughout the six-month study. The accu-
racy of, and differences between, responder rates should, however, be
interpreted with caution due to the small number of patients. Overall, ruﬁ-
easonablywell tolerated in this group
d epilepsies, although a subgroup of
pilepsy with myoclonic seizures were
nt.
pilepsy, anticonvulsant, childrenorrespondence:
i Joong Kim
namide appeared to be effective and r
of children with refractory generalise
patients with Dravet syndrome and e
less responsive to ruﬁnamide treatme
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Ruﬁnamide, a triazole derivative
(1-[2,6-diﬂuorophenyl]methyl)-1-
hydro-1,2,3-triazole-carboxamide),
is a novel antiepileptic drug which
has a different chemical structure
from other antiepileptic drugs.
Favourable characteristics as an
antiepileptic drug include a broad
spectrum of anticonvulsant activity,
good oral absorption, low propen-
sity for drug interactions, and a
modest side effect proﬁle (Cheng-
Hakimian et al., 2006). Studies have
demonstrated its efﬁcacy in various
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nimal models of partial, generalised tonic-clonic,
bsence, and clonic seizures (Hakimian et al., 2007).
remarketing studies have suggested that ruﬁnamide
s efﬁcacious in the treatment for both partial and
eneralised seizures (Pålhagen et al., 2001). How-
ver, currently, the drug is approved only for use
s adjunctive treatment for seizures associated with
ennox-Gastaut syndrome.
tudies of ruﬁnamide treatment in heterogeneous
roups, mainly focusing on Lennox-Gastaut syndrome
Coppola et al., 2010; Vendrame et al., 2010), have
hown promising results (Kluger et al., 2009; Kluger
t al., 2010a; Coppola et al., 2011). Additionally, some
ecent studies conducted for one or two speciﬁc
pilepsy syndromes, such as epileptic spasms (Olson
t al., 2011) and epilepsy with myoclonic absences
Häusler et al., 2011), have demonstrated that ruﬁ-
amide is effective in the treatment for other epilepsy
yndromes as well. In contrast to the favourable
esponses for other generalised epilepsies, a recent
tudy reported adisappointingoutcomeof ruﬁnamide
reatment in patients with Dravet syndrome (Mueller
t al., 2011).
nhibition of sodium channel activity has generally
een postulated to be the principalmechanismof ruﬁ-
amide action (Arroyo, 2007). However, since other
rugs that act at the sodium channel, such as car-
amazepine and phenytoin, are known to aggravate
yoclonic and atypical absence seizures (Somerville,
009), ruﬁnamide may also elicit similar responses.
hus, the responses in patients with speciﬁc seizure
ypes or syndromes should be further delineated
n order to determine the efﬁcacy of ruﬁnamide in
he context of each disorder and establish the most
avourable indications for this drug.
n this study, we evaluated the efﬁcacy and safety of
uﬁnamide adjunctive therapy in children with refrac-
ory generalised epilepsy, and further assessed the
fﬁcacy of ruﬁnamide in related epilepsy syndromes
nd seizure types.
ethods
retrospective chart review was performed with the
pproval of the Institutional Review Board of Seoul
ational University Children’s Hospital. Sixty-ﬁve chil-
renwith epilepsy received ruﬁnamide in the Pediatric
eurology Division of the above-mentioned hospital0
rom May 2010 to April 2011. Data from the charts of 53
hildren meeting the following criteria were analysed:
1) between 4 and 18 years of age; (2) diagnosed with
eneralised epilepsy by EEG or video-EEG; (3) more
han one seizure per month; and (4) seizures refrac-
ory to at least two antiepileptic drugs. Twelve children
ere excluded because they received either a keto-
a
i
p
s
a
w
renic diet or had a corpus callosotomy during the
tudy period. Patients with only absence seizureswere
ot included since absence seizures are often difﬁcult
o deﬁne and count.
aseline data was obtained from the medical records
f each patient. Age, sex, underlying aetiology, body
eight,previous seizure typesanddiagnosis, presence
f mental retardation/developmental delay, concomi-
ant drug use, magnetic resonance images, video-EEG
ecords, and EEG results were collected and reviewed.
eizure semiology, seizure frequency, ruﬁnamide
tart and end dates, initial dose, maximal dose, and
dverse events reported during the study period were
ssessed.
hediagnosis of eachpatientwasestablishedbasedon
he International League Against Epilepsy (1981, 2010)
lassiﬁcation of seizures and epilepsy syndromes.
atients were classiﬁed as having Lennox-Gastaut syn-
romeonlywhen theyhad tonic seizures documented
n medical records or based on video-EEG, intractable
eizures, mental retardation, and slow spike-wave dis-
harges on EEG. Patients were classiﬁed as having
ravet syndrome when they had had normal develop-
ent before seizure onset, seizures starting before
year of age, seizures mainly triggered by fever, pro-
onged convulsive seizures (longer than 15 minutes),
ater occurrence of seizures of various types, and
ater cognitive regression (Depienne et al., 2009). Diag-
oses were supported by genetic analysis, if possible.
f patients could not be diagnosed with any speciﬁc
pilepsy syndrome, they were further classiﬁed as
aving epilepsywith spasms/tonic seizures or epilepsy
ith myoclonic seizures according to their predomi-
ant seizure types. Seizures were classiﬁed according
o the International League Against Epilepsy classiﬁ-
ation and were identiﬁed based on either previous
ideo-EEGmonitoringorcurrent clinical examinations.
bsences or partial seizures reported by caregivers
ere classiﬁed as “others”.
aseline seizure frequency was determined by asking
aregivers to count different seizure types separately
uring the month before the initiation of ruﬁnamide.
hen, the frequency of each seizure type was evaluat-
d during each visit to the clinic by asking the care-
ivers to estimate the frequency of seizures during
he follow-up period, relative to the baseline. The
fﬁcacy of treatment was determined by assessing
he total monthly seizure frequency and indivi-
ual seizure types at three months and six monthsEpileptic Disord, Vol. 15, No. 1, March 2013
fter ruﬁnamide initiation. Patients were classiﬁed
nto the following four categories, according to the
ercentage of seizure reduction: (1) seizure-free; (2)
eizure reduction ≥50%; (3) seizure reduction <50%;
nd (4) no change or aggravation of seizures. Patients
ith more than 50% seizure reduction were deﬁned as
esponders.
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rhe initial dose of ruﬁnamide ranged from 5-
0 mg/kg/day. Each patient then visited the clinic
egularly every 2-4 weeks, and the dose of ruﬁnamide
as increased by 10-20 mg/kg at each visit, depending
n the response. The maximum dose for each patient
aried from 20-80 mg/kg/day. Adverse events reported
y patients or caregivers during ruﬁnamide therapy
ere recorded.
esults
atient characteristics
f the 53 enrolled subjects, 20 had Lennox-Gastaut
yndrome. The rest of the patients included 5 with
ravet syndrome and 28 with unclassiﬁed generalised
pilepsy.Amongpatientswithunclassiﬁedgeneralised
pilepsy, 13 were further classiﬁed as having epilepsy
ith spasms/tonic seizures and 5 were further classi-
ed as having epilepsy with myoclonic seizures.
he mean follow-up period was 9.9 months (range:
-12 months) and the mean duration of ruﬁnamide
reatment was 7.6 months (range: 0.4-12 months). The
ean initial dose was 12.4 mg/kg/day (range: 5.6-
3.5 mg/kg/day), and the mean maximal dose was
0.2 mg/kg/day (range: 6.7-83.3 mg/kg/day). Additionalpileptic Disord, Vol. 15, No. 1, March 2013
atient characteristics are listed in table 1.
he mean number of concomitant antiepileptic drugs
as 3.6 (range: 1-6). Four patients with Lennox-Gastaut
yndrome had more than ﬁve baseline antiepileptic
rugs, and these patients had multiple seizure types
hat were very sensitive to changes in antiepileptic
Table 1. Patient characteristics.
Characteristics Value
Male : Female 32:21
Mean age (years)* 7.9 (4-17.3)
Symptomatic 22
Hypoxic-ischemic encephalopathy 11
Malformation of cortical development 4
Neurocutaneous syndrome 2
Others 5
Cryptogenic 31
Epilepsy syndrome
Lennox-Gas taut syndrome 20
Dravet syndrome 5
Unclassiﬁed generalized epilepsy 28
Epilepsy with spasms/tonic seizures 13
Epilepsy with myoclonic seizures 5
History of ketogenic diet 22
History of corpus callosotomy 6
Number of concomitant antiepileptic drugs* 3 (1-6)
Median, range
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oRuﬁnamide in childhood generalised epilepsy
rugs. The most frequently used antiepileptic drugs
t the time of ruﬁnamide treatment were lamotri-
ine (37/53), levetiracetam (28/53), topiramate (28/53),
lobazam (26/53), and valproate (18/53). A compari-
on of response rates in patients receiving different
oncomitant antiepileptic drugs showed no statisti-
ally signiﬁcant difference (data not shown).
fﬁcacy
mong the 53 patients, 37.7% (20/53) were classiﬁed as
esponders at three months. The number of respon-
ers decreased to 34.0% (18/53) at six months. The
umber of seizure-free patients was 9 (17.0%) and 5
9.4%) at three and six months, respectively.
hen outcomes were evaluated according to epilepsy
yndromes, 40.0% (8/20) of patients with Lennox-
astaut syndrome had more than 50% seizure
eduction at three months. Twenty per cent (1/5) of
atients with Dravet syndrome responded to ruﬁ-
amide therapy. Patients with unclassiﬁed generalised
pilepsy showed a response rate of 39.3% (11/28), and
hen these patients were further subdivided accord-
ng to their predominant seizure types, those with
pilepsy andspasms/tonic seizures showeda response
ate of 38.5% (5/13), while those with epilepsy and
yoclonic seizures had a response rate of 20.0% (1/5).
his trend was sustained for six months. Detailed
esults are presented in table 2.
he response rates for each seizure type after three
nd six months of ruﬁnamide therapy are presented
n table 3. The response rates related to seizure type
anged from21.1 to 60.0%at threemonths; tonic-clonic
eizures (60.0%; 3/5), tonic seizures (32.3%; 10/31),
tonic seizures (36.4%; 4/11), spasms (55.6%; 5/9), and
yoclonic seizures (21.1%; 4/19).
hen response rates for each seizure type were
valuated in patients with Lennox-Gastaut syndrome
xclusively, response rates for atonic head drops, tonic
eizures, and tonic-clonic seizures were 66.7% (4/6),
0% (9/15), and 33.3% (1/3), respectively. The response
ateswere lower formyoclonic seizures and spasms, at
6.7% (1/6) and 25.0% (1/4), respectively, in this patient
roup.
afety and tolerability
wenty-three (43.4%) patients or their carers reported
4 adverse events during the study. Somnolence, poor51
ppetite, andbehavioural changeswere themost com-
on problems. Other adverse events are described in
able 4. Most of the adverse events were transient and
ild. Adverse events all subsided spontaneously or
fterdiscontinuationof ruﬁnamide.Nospeciﬁcconco-
itant anticonvulsants were found to increase the risk
f adverse events (data not shown).
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Table 2. Response to ruﬁnamide according to epilepsy syndrome.
3 months 6 months
Epilepsy syndrome N Seizure-free
(%)
>50% seizure
reduction (%)
Seizure-free
(%)
>50% seizure
reduction (%)
Lennox-Gastaut syndrome 20 4 (20.0) 8 (40.0) 1 (5.0) 6 (30.0)
Dravet syndrome 5 0 (0.0) 1 (20.0) 0 (0.0) 1 (20.0)
Unclassiﬁed generalized epilepsy 28 5 (17.9) 11 (39.3) 4 (14.3) 11 (39.3)
Epilepsy with spasms/tonic seizures 13 3 (23.1) 5 (38.5) 3 (23.1) 5 (38.5)
Epilepsy with myoclonic seizures 5 0 (0.0) 1 (20.0) 0 (0.0) 1 (20.0)
Total 53 9 (17.0) 20 (37.7) 5 (9.4) 18 (34.0)
Table 3. Response to ruﬁnamide according to seizure type.
Seizure type 3 months 6 months
N Seizure free (%) > 50% seizure reduction (%) Seizure free (%) > 50% seizure reduction (%)
Tonic 31 5 (16.1) 10 (32.3) 3 (9.7) 9 (29.0)
Myoclonic 19 1 (5.3) 4 (21.1) 1 (5.3) 4 (21.1)
*
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aAtonic 11 2 (18.2) 4 (36.4)
Spasms 9 2 (22.2) 5 (55.6)
Tonic-clonic 5 1 (20.0) 3 (60.0)
Others* 15 4 (26.7) 9 (60.0)
Others, including absences and partial seizures
uﬁnamide was discontinued in 14 patients (26.4%)
uring the study period; in 6 patients (11.3%) because
herewasno improvement in seizure frequency, and in
further 6 (11.3%) following an increase in seizure fre-
uency. The results are shown in table 5. Two patients
iscontinued ruﬁnamide due to adverse events (2/53;
.8%); the reasons for discontinuation were the
resence of a rash and behavioural problems.
iscussion
lthough ruﬁnamide was originally approved only for
he treatment of Lennox-Gastaut syndrome (Glauser
t al., 2008), many studies have recently investigated
he efﬁcacy of ruﬁnamide for the treatment of other
eneralised epilepsy syndromes. However, most of2
hese studies were performed in limited populations
f patients with only a single epilepsy syndrome
Olson et al., 2011; Häusler et al., 2011; Mueller
t al., 2011; Joseph et al., 2011), and a comparison
f the outcomes between different epilepsy syn-
romes was not possible (Coppola et al., 2011). Since
eneralised epilepsy syndromes other than Lennox-
m
r
P
a
T
A
ﬁ1 (9.1) 3 (27.3)
1 (11.1) 3 (33.3)
1 (20.0) 3 (60.0)
2 (13.3) 8 (53.3)
astaut syndrome constitute a signiﬁcant proportion
f intractable generalised epilepsies, and speciﬁc syn-
romic classiﬁcation is not always feasible, responses
o ruﬁnamide treatment for Lennox-Gastaut syn-
rome, unclassiﬁed generalised epilepsy, and other
eneralised epilepsy syndromes should be evaluated
n patients together, as a single cohort.
n the present study, the overall response rates at
hree months and six months after initiation of ruﬁ-
amide treatment (37.7 and 34%, respectively) were
avourable. However, response tended to vary accord-
ng to the speciﬁc epilepsy syndrome. While patients
ith Lennox-Gastaut syndrome and epilepsy with
pasms/tonic seizures responded favourably, with up
o a 40% response rate at three months, patients with
ravet syndrome only showed a 20% response rate
t three months. Notably, patients with epilepsy andEpileptic Disord, Vol. 15, No. 1, March 2013
yoclonic seizures also showed a lower response
ate (20%), similar to patients with Dravet syndrome.
atientswithunclassiﬁedgeneralisedepilepsy showed
response rate of 39.3% at three and six months.
hese ﬁndings correlate well with previous studies.
n earlier study conducted in patients with unclassi-
ed generalised epilepsy reported a similar response
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Table 4. Adverse events reported by caregivers
during ruﬁnamide adjunctive therapy.
Adverse events N Number of patients
who discontinued
ruﬁnamide (%)
Somnolence 8
Poor appetite 5
Behavioral problems 3 1 (1.9)
Enuresis 2
Tremor 2
Ataxia 1
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wDrooling 1
Nausea 1
Rash 1 1 (1.9)
ate (42.8%) after three months of ruﬁnamide therapy
Kluger et al., 2009). In another study, patients with
pileptic spasms also showed a high response rate
52.6%; 20/38) (Olson et al., 2011), while a different
tudy in patients with Dravet syndrome demonstrated
response rate of 20.0% (4/20) at six months (Muellerpileptic Disord, Vol. 15, No. 1, March 2013
t al., 2011).
hen the efﬁcacy of ruﬁnamide for different seizure
ypes in Lennox-Gastaut syndrome was evaluated, the
esults were consistent with earlier studies. Atonic
ead drops were the best responding seizure type in
arlier studies, as well as in this study, with response
ates ranging from 47.0-78.9% after various durations
F
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Table 5. Patients who experienced aggravati
Case Age Sex Epilepsy
syndrome
Habitual seizure Ag
de
1 8 M Dravet syndrome Tonic To
2 15 M Dravet syndrome Myoclonic, atonic My
ep
3 4 F Dravet syndrome Myoclonic,
tonic-clonic
My
ton
4 7 M Lennox-Gastaut
syndrome
Tonic My
5 12 F Lennox-Gastaut
syndrome
Myoclonic My
6 1-1 M Unclassiﬁed
generalized
epilepsy
Atonic,
tonic-clonic
Ab
epRuﬁnamide in childhood generalised epilepsy
f treatment (Kluger et al., 2009; Kluger et al., 2010b;
oppola et al., 2010; Vendrame et al., 2010). Tonic
eizures also showed a good response rate in the
bove studies, while tonic-clonic seizures (response
ate: 11.6-37.5%) (Kluger et al., 2009; Coppola et al.,
010) and spasms (response rate: 30.8%) (Vendrame
t al., 2010) showed lower response rates, similar to
he present study.
orsening of seizures after ruﬁnamide use occurred
n 6 patients in the present study. Of the different
pilepsy syndromes, this was most frequently asso-
iated with Dravet syndrome and myoclonic seizures
ere the most commonly aggravated seizure type.
he low efﬁcacy of ruﬁnamide for the treatment of
yoclonic seizures may be the reason for the poor
utcome of patients with this syndrome. However,
odium channel-blocking agents, such as lamotrigine
ndcarbamazepine,havebeenpostulated toaggravate
eizures by decreasing the sodium current density in
nhibitory interneurons in patients with pre-existing
oss of function of Nav1.1 (voltage-gated sodium chan-
el), such as patients with Dravet syndrome (Liao
t al., 2010). Theworseningof seizureswith ruﬁnamide,
hich is thought to act on sodium channels, may be
ttributable to a similar mechanism. An earlier study
eportedaggravationof seizures in30%(6/20)ofDravet
yndromepatients, but the speciﬁc typeof seizure that
as aggravatedwas not identiﬁed (Mueller et al., 2011).53
urther studies are required.
he adverse effects appear to be mild and transient
ith spontaneous resolution, according to previous
hort- and long-term studies of ruﬁnamide therapy.
ommonly reported effects were fatigue, poor
ppetite, and behavioural problems (Kluger et al.,
009). The present study showed similar results.
on of seizures after ruﬁnamide therapy.
gravated or newly
veloped seizure
Duration
of ruﬁnamide
therapy (days)
Initial ruﬁnamide
dose (mg/kg/d)
nic, tonic-clonic 29 20
oclonic status
ilepticus
13 14
oclonic,
ic-clonic
14 14
oclonic 43 18
oclonic 34 14
sence status
ilepticus
23 13
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mong our 53 patients, 12 (24.5%) discontinued
uﬁnamide during the study period. One patient dis-
ontinued due to rash, which developed after two
onths of therapy and subsided within ﬁve days
fter discontinuation. A recent study of patients with
ennox-Gastaut syndrome reported a higher occur-
ence of rash (2.7%) with ruﬁnamide, compared to
lacebo (Kluger et al., 2010b). The development of rash
ith ruﬁnamide use has also been reported in other
tudies (Vendrame et al., 2010; Joseph et al., 2011). Fur-
her studies to evaluate the prevalence of rash with
uﬁnamide treatment are required.
his study has several limitations, including the study
ize and retrospective study design. This was an open-
abel study and did not include a control group.
nly selected patients with very refractory epilepsy
ere included, and some epilepsy syndromes, such
s myoclonic-atonic epilepsy, were excluded. Further
rospective studies are required to assess the efﬁ-
acy of ruﬁnamide in these syndromes. In addition,
hen patients were stratiﬁed into different epilepsy
yndromes, patient number per each group was
ery small, and consequently statistically signiﬁcant
hanges would not have been expected because the
tudy was under-powered. The conﬁdence limits are
ery wide and the results should thus be interpreted
ith caution.
owever, the value of this study is in the conﬁrmation
f recent reports which demonstrate the efﬁcacy and
olerability of ruﬁnamide treatment for patients with
efractory generalised epilepsies, other than Lennox-
astaut syndrome. The efﬁcacy of ruﬁnamide should
e further evaluated in speciﬁc syndromes and seizure
ypes, particularly sinceour current study suggests that
uﬁnamide might have a low efﬁcacy against genera-
ised epilepsy syndromes presenting with myoclonic
eizures. 
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